Evidence map›Paper›PMID 42129009›Full record

ArticleEJNMMI research2026

[

Silu Liu, Qingqing Pan, Hongzhe Zhang, Linyi Peng, Wen Zhang, YunLu Feng, Yaping Luo

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04125511 (Characterizing IgG4-related Disease With 68Ga-FAPI PET/CT), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04125511 early_phase1unknown statusnot on this map

Characterizing IgG4-related Disease With 68Ga-FAPI PET/CT

TypeinterventionalSponsorPeking Union Medical College HospitalRan2019 to 2021Enrolled100ConditionsIgG4-related DiseaseArms68Ga-FAPI
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Silu LiuDepartment of Nuclear Medicine, State Key Laboratory of Common Mechanism Research for Major Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, No.1 Shuaifuyuan Wangfujing, Dongcheng District, Beijing, 100730, P. R. China.
Qingqing PanDepartment of Nuclear Medicine, State Key Laboratory of Common Mechanism Research for Major Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, No.1 Shuaifuyuan Wangfujing, Dongcheng District, Beijing, 100730, P. R. China.
Hongzhe ZhangDepartment of Nuclear Medicine, State Key Laboratory of Common Mechanism Research for Major Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, No.1 Shuaifuyuan Wangfujing, Dongcheng District, Beijing, 100730, P. R. China.
Linyi PengDepartment of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, Beijing, 100730, P. R. China.
Wen ZhangDepartment of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, Beijing, 100730, P. R. China.
YunLu FengDepartment of Gastroenterology, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, Beijing, 100730, P. R. China.
Yaping LuoDepartment of Nuclear Medicine, State Key Laboratory of Common Mechanism Research for Major Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, No.1 Shuaifuyuan Wangfujing, Dongcheng District, Beijing, 100730, P. R. China. luoyaping@live.com.ORCID http://orcid.org/0000-0002-5787-1136

Funding

CAMS Innovation Fund for Medical Sciences 2024-I2M-C&T-B-034National High Level Hospital Clinical Research Funding 2025-PUMCH-D-003, 2025-PUMCH-C-024National Key Research and Development Program of China 2024YFF0507702Peking Union Medical College Hospital Talent Cultivation Program UBJ10707
6 · The paper itself

Abstract

backgroundRecently, two subtypes of immunoglobulin G4-related disease (IgG4-RD), proliferative type and fibrotic type, were defined according to patients' clinicopathological characteristics. The objective of this study is to determine the difference of fibrotic activity shown in [

resultsSixty-eight IgG4-RD patients (50 proliferative subtype, 18 fibrotic subtype; 47 newly diagnosed treatment-naïve, 21 with relapsed or persistent disease after treatment) who underwent [

conclusionThe proliferative subtype of IgG4-RD exhibited more dominant uptake of [

trial registrationClinicalTrials. NCT04125511 (Characterizing IgG4RD With 68GaFAPI PET/CT). Registered 14 October 2019, https//clinicaltrials.gov/study/NCT04125511?cond=NCT04125511&rank=1.

Indexed as

[68Ga]Ga-FAPI-04fibrotic subtypeIgG4-related diseasePET/CTproliferative subtype

Identifiers

PMID42129009
PMCPMC13341578

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.